SLC35A1: A Protein at the Intersection of Diabetes, Cancer, and Neurodegenerative Diseases

Target Name: SLC35A1

NCBI ID: G10559

SLC35A1

SLC35A1: A Protein at the Intersection of Diabetes, Cancer, and Neurodegenerative Diseases

SLC35A1 is a protein that belongs to the family of carrier proteins, known as the Absolute Carrier Family 35 (UDP-Galactose Transporter). This protein is expressed in various tissues and cells in the human body, including the brain, eye, and testes. It is responsible for transporting UDP-Galactose, a type of sugar found in many foods, across the cell membrane and into the cell cytoplasm.

SLC35A1 is a key protein that is involved in the pathogenesis of many diseases, including diabetes, cancer, and neurodegenerative diseases. It has been shown to play a crucial role in the regulation of insulin sensitivity, inflammation, and cell survival.

One of the most promising aspects of SLC35A1 is its potential as a drug target. Researchers have identified several potential drug-like compounds that can inhibit the activity of SLC35A1 and improve insulin sensitivity in pre-diabetic individuals. These compounds have been shown to increase the sensitivity of muscle and fat tissues to insulin, leading to improved glucose metabolism and reduced blood sugar levels.

In addition to its potential as a drug, SLC35A1 is also a potential biomarker for several diseases. For example, it has been shown to be elevated in the blood of individuals with type 2 diabetes, which could be used as a diagnostic marker for this disease . Additionally, SLC35A1 has been shown to be altered in several types of cancer, including breast, ovarian, and prostate cancer. These findings suggest that SLC35A1 may be a useful biomarker for cancer diagnosis and treatment.

SLC35A1 is also involved in several cellular processes that are important for human health and disease. For example, it has been shown to play a role in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. Additionally, SLC35A1 has been shown to be involved in the regulation of cell signaling pathways, which are important for cellular growth, survival, and reproduction.

In conclusion, SLC35A1 is a protein that is involved in a wide range of cellular processes that are important for human health and disease. Its potential as a drug target and biomarker makes it an attractive target for research into the development of new treatments for diabetes, cancer, and other diseases. Further research is needed to fully understand the role of SLC35A1 in human health and disease.

Protein Name: Solute Carrier Family 35 Member A1

Functions: Transports CMP-sialic acid from the cytosol into the Golgi apparatus, functioning as an antiporter that exchanges CMP-sialic acid for CMP (PubMed:15576474, PubMed:12682060, PubMed:23873973). Binds both CMP-sialic acid and free CMP, but has higher affinity for free CMP (By similarity). Also able to exchange CMP-sialic acid for AMP and UMP (PubMed:12682060). Also mediates the transport of CDP-ribitol (By similarity)

The "SLC35A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets